235 related articles for article (PubMed ID: 28397047)
1. Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials.
Zhuang X; Xiao YP; Tan LH; Wang LT; Cao Q; Qu GF; Xiao S; Duan HX
J Huazhong Univ Sci Technolog Med Sci; 2017 Apr; 37(2):172-178. PubMed ID: 28397047
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine alone or in combination with Cisplatin for advanced biliary tract carcinomas: an overview of clinical evidence.
Sun TT; Wang JL; Fang JY
Asian Pac J Cancer Prev; 2013; 14(2):877-83. PubMed ID: 23621255
[TBL] [Abstract][Full Text] [Related]
5. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
Vogel A; Kasper S; Bitzer M; Block A; Sinn M; Schulze-Bergkamen H; Moehler M; Pfarr N; Endris V; Goeppert B; Merx K; Schnoy E; Siveke JT; Michl P; Waldschmidt D; Kuhlmann J; Geissler M; Kahl C; Evenkamp R; Schmidt T; Kuhlmann A; Weichert W; Kubicka S
Eur J Cancer; 2018 Mar; 92():11-19. PubMed ID: 29413685
[TBL] [Abstract][Full Text] [Related]
6. Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis.
Zheng T; Jin J; Zhou L; Zhang Y
Oncol Res Treat; 2020; 43(9):460-469. PubMed ID: 32629449
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
8. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.
Kameda R; Ando T; Kobayashi S; Ueno M; Ohkawa S
Jpn J Clin Oncol; 2013 Jun; 43(6):636-40. PubMed ID: 23619988
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis.
Yang R; Wang B; Chen YJ; Li HB; Hu JB; Zou SQ
Anticancer Drugs; 2013 Sep; 24(8):871-7. PubMed ID: 23799294
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Valle J; Wasan H; Palmer DH; Cunningham D; Anthoney A; Maraveyas A; Madhusudan S; Iveson T; Hughes S; Pereira SP; Roughton M; Bridgewater J;
N Engl J Med; 2010 Apr; 362(14):1273-81. PubMed ID: 20375404
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.
Takahara N; Isayama H; Nakai Y; Sasaki T; Ishigaki K; Saito K; Akiyama D; Uchino R; Mizuno S; Yagioka H; Kogure H; Togawa O; Matsubara S; Ito Y; Toda N; Tada M; Koike K
Invest New Drugs; 2017 Jun; 35(3):269-276. PubMed ID: 28124197
[TBL] [Abstract][Full Text] [Related]
15. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program.
Moehler M; Maderer A; Ehrlich A; Foerster F; Schad A; Nickolay T; Ruckes C; Weinmann A; Sivanathan V; Marquardt JU; Galle PR; Woerns M; Thomaidis T
BMC Cancer; 2019 Jan; 19(1):55. PubMed ID: 30634942
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
Woo SM; Lee WJ; Kim JH; Kim DH; Han SS; Park SJ; Kim TH; Lee JH; Koh YH; Hong EK
Chemotherapy; 2013; 59(3):232-8. PubMed ID: 24356333
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: a meta-analysis.
Liu H; Zhang QD; Li ZH; Zhang QQ; Lu LG
World J Gastroenterol; 2014 Dec; 20(47):18001-12. PubMed ID: 25548500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
